Trial Profile
Comparison of Apixaban and Warfarin in Non-Valvular Atrial Fibrillation Patients: a real world study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2018 New trial record
- 14 Nov 2018 Results comparing the risk of discontinuation of Apixaban or Warfarin in non-valvular atrial fibrillation patients, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.